312 related articles for article (PubMed ID: 33077919)
1. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
3. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
4. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
[TBL] [Abstract][Full Text] [Related]
5. HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma.
Banet N; Shahi M; Batista D; Yonescu R; Tanner EJ; Fader AN; Cimino-Mathews A
Am J Surg Pathol; 2021 May; 45(5):708-715. PubMed ID: 33739786
[TBL] [Abstract][Full Text] [Related]
6. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
[TBL] [Abstract][Full Text] [Related]
7. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
8. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
[TBL] [Abstract][Full Text] [Related]
9. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
10. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
[TBL] [Abstract][Full Text] [Related]
11. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
Yang SR; Bouhlal Y; De La Vega FM; Ballard M; Kuo CJ; Vilborg A; Jensen G; Allison K
Mod Pathol; 2020 Aug; 33(8):1546-1556. PubMed ID: 32161378
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract][Full Text] [Related]
14. HER2 Status Assessment in Endometrial Serous Carcinoma: Comparative Analysis of Two Proposed Testing and Interpretation Algorithms.
Hashem S; Zare SY; Fadare O
Int J Gynecol Pathol; 2024 Jan; 43(1):4-14. PubMed ID: 37406350
[TBL] [Abstract][Full Text] [Related]
15. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
[TBL] [Abstract][Full Text] [Related]
16. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry.
Morsberger L; Pallavajjala A; Long P; Hardy M; Park R; Parish R; Nozari A; Zou YS
Cancer Cell Int; 2022 Nov; 22(1):350. PubMed ID: 36376842
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
18. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Klc TR; Wu S; Wilhite AM; Jones NL; Powell MA; Olawaiye A; Girda E; Brown J; Puechl A; Ali-Fehmi R; Winer IS; Herzog TJ; Korn WM; Erickson BK
Gynecol Oncol; 2022 Nov; 167(2):289-294. PubMed ID: 36114027
[TBL] [Abstract][Full Text] [Related]
19. HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization.
Kıvrak H; Özakıncı H; Karasoy D; Dizbay Sak S
Balkan Med J; 2022 Jan; 39(1):21-29. PubMed ID: 34928234
[TBL] [Abstract][Full Text] [Related]
20. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
